Lunit Inc
KOSDAQ:328130
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lunit Inc
Total Liabilities & Equity
Lunit Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lunit Inc
KOSDAQ:328130
|
Total Liabilities & Equity
₩16.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
I
|
Infinitt Healthcare Co Ltd
KOSDAQ:071200
|
Total Liabilities & Equity
₩232.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
U
|
UBCare Co Ltd
KOSDAQ:032620
|
Total Liabilities & Equity
₩227.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
13%
|
|
|
L
|
LifeSemantics Corp
KOSDAQ:347700
|
Total Liabilities & Equity
₩44.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
e
|
ezCaretech Co Ltd
KOSDAQ:099750
|
Total Liabilities & Equity
₩56.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
J
|
JLK Inc
KOSDAQ:322510
|
Total Liabilities & Equity
₩69.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Lunit Inc
Glance View
Lunit Inc., founded in South Korea, stands as a pioneering force in the application of artificial intelligence within the realm of medical technology. As a company at the intersection of healthcare and cutting-edge AI, Lunit crafts advanced solutions that enhance the diagnostic processes in radiology and oncology. The company's name, derived from "learning unit," underscores its mission to employ deep learning as a core component in transforming medical diagnostics. At the heart of Lunit’s operations are their flagship products, Lunit INSIGHT and Lunit SCOPE, which are designed to empower physicians by providing highly accurate diagnostic readings and treatment predictions. With this technology, Lunit aims to reduce diagnostic errors and improve the efficiency of medical imaging analysis, ultimately enhancing patient treatment outcomes. Lunit generates revenue through strategic partnerships and sales of their AI software solutions to hospitals and healthcare providers globally. The company's business model involves not only licensing its AI technologies but also integrating them with existing medical imaging equipment, thus enhancing the value derived from traditional diagnostic tools. By collaborating with prominent medical device manufacturers and healthcare institutions, Lunit ensures both the scalability and adaptability of its products in diverse clinical settings. Additionally, they actively engage in research collaborations and pilot programs to further their technological advancements and expand their market presence. Through these endeavors, Lunit is steadily carving out a crucial role in the healthcare sector by offering AI-driven solutions that promise to revolutionize patient care.
See Also
What is Lunit Inc's Total Liabilities & Equity?
Total Liabilities & Equity
16.9B
KRW
Based on the financial report for Dec 31, 2024, Lunit Inc's Total Liabilities & Equity amounts to 16.9B KRW.
What is Lunit Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-15%
Over the last year, the Total Liabilities & Equity growth was 24%. The average annual Total Liabilities & Equity growth rates for Lunit Inc have been -44% over the past three years , -15% over the past five years .